Dong M, Nio Y, Guo K J, Tamura K, Tian Y L, Dong Y T
First Department of Surgery, Shimane Medical University, Izumo, Japan.
Anticancer Res. 1998 Nov-Dec;18(6B):4613-9.
The expression of epidermal growth factor (EGF) and its receptor (EGFR) was studied immunohistochemically in fifty-seven Chinese patients with primary invasive ductal carcinoma (IDC) of the pancreas. The frequency of expression of EGF and EGFR was 73.7% and 68.4%, respectively. The frequency of their co-expression was 61.4%. No significant relationships were seen between the expression of EGF and its receptor and the patients' age, gender, site of the tumor, stage, and grade. Positive co-expression of EGF and EGFR was significantly associated with the poor prognosis. The median survival of the EGF(-)EGFR(-) group for 17.2 months was longer than that of the EGF(+)EGFR(+) group for 9.7 months (p = 0.02), as well as that of the other groups of EGR(+)EGFR(-), EGF(-)EGFR(+), and EGF(+)EGFR(+) for 9.9 month (p = 0.03). These results suggested that EGF and EGFR were frequently expressed in Chinese patients with IDC of the pancreas. Their co-expression may be a useful prognostic indicator for pancreatic cancer.
采用免疫组织化学方法，对57例中国原发性胰腺浸润性导管癌（IDC）患者的表皮生长因子（EGF）及其受体（EGFR）的表达情况进行了研究。EGF和EGFR的表达频率分别为73.7%和68.4%。它们的共表达频率为61.4%。EGF及其受体的表达与患者的年龄、性别、肿瘤部位、分期和分级之间均未发现显著相关性。EGF和EGFR的阳性共表达与预后不良显著相关。EGF(-)EGFR(-)组的中位生存期为17.2个月，长于EGF(+)EGFR(+)组的9.7个月（p = 0.02），也长于EGR(+)EGFR(-)、EGF(-)EGFR(+)和EGF(+)EGFR(+)其他组的9.9个月（p = 0.03）。这些结果表明，EGF和EGFR在中国胰腺IDC患者中经常表达。它们的共表达可能是胰腺癌一个有用的预后指标。
